First-in-human Single Ascending Dose Study of LNA043 in Patients Scheduled for Total Knee Replacement
A Randomized, Placebo Controlled, Double-blind First-in-human Single Ascending Dose Study of LNA043 in Primary Osteoarthritis Patients Scheduled for Total Knee Replacement
Sponsor: Novartis Pharmaceuticals
This PHASE1 trial investigates Primary Osteoarthritis Patients Scheduled for Total Knee Replacement Surgery and is currently completed. Novartis Pharmaceuticals leads this study, which shows 11 recorded versions since 2015 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Sep 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Jun 2018 — Sep 2018 [monthly]
Completed PHASE1
▶ Show 6 earlier versions
-
May 2018 — Jun 2018 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Oct 2017 — May 2018 [monthly]
Recruiting PHASE1
-
Jun 2017 — Oct 2017 [monthly]
Recruiting PHASE1
-
Apr 2017 — Jun 2017 [monthly]
Recruiting PHASE1
-
Feb 2017 — Apr 2017 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Nov 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .